세계 항방사선 의약품 시장 규모는 2024년부터 2030년까지 예측 기간 동안 8.79%의 연평균 복합 성장률(CAGR)로 확대될 것으로 예상됩니다. 항방사선 의약품에 대한 수요는 주로 암 진단 절차에 따른 부작용 증가, 방사선 또는 원자력 사고로 인한 피폭 위험의 급증, 핵보유국의 방사능 보호에 대한 관심 증가 등으로 인해 2024년부터 2030년까지 예측 기간 동안 전체 항방사선 의약품 시장의 성장에 기여할 것으로 예상됩니다.
FDA에 따르면 컴퓨터 단층 촬영(CT), 엑스레이 촬영, 전통적인 유방 조영술 등 많은 의료용 영상 진단 장비는 전리 방사선을 사용하여 신체 이미지를 생성합니다. 이러한 이온화 방사선은 DNA를 손상시켜 암 발생 위험을 증가시킬 수 있습니다.
또한 국립보건원(NIH), 질병예방통제센터(CDC), 식품의약국(FDA) 등 여러 미국 정부 기관으로 구성된 국가독성프로그램(NTP)은 엑스레이와 감마선을 인체 발암물질로 분류하고 있습니다.
미국 국립암연구소(NCI)의 2019년 보고서에 따르면, 15세 이전에 CT 스캔을 여러 번 받은 환자는 백혈병과 뇌종양 발병 위험이 높아지는 것으로 나타났습니다. 또한, 때로는 높은 수준의 방사선 노출이 조직에 영향을 미쳐 탈모, 피부 발적, 백내장 등을 유발하여 약물 항방사선 치료의 필요성을 악화시킬 수 있습니다.
따라서 영상진단 시 높은 이온화 방사선 노출과 그 부작용으로 인한 안전성에 대한 우려가 항방사선 의약품에 대한 수요를 증가시킬 것으로 예상됩니다.
이 보고서는 세계 항방사선 의약품 시장에 대해 조사했으며, 시장 개요와 함께 화합물별/적응증별/방사선 유형별/유통 채널별/지역별 동향, 시장 진출기업 프로파일 등의 정보를 제공합니다.
Anti-Radiation Drugs Market By Compound (Potassium Iodide, Prussian Blue, Diethylenetriamine Pentaacetic Acid, Colony Stimulating Factors, And Others), Indication (Acute Radiation Syndrome, Cancer Treatment, And Others), Radiation Type (Ionizing Radiations And Non-Ionizing Radiations), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, And Others) and geography is expected to grow at a steady CAGR forecast till 2030 owing increasing number side effects associated cancer diagnostic procedures and surge in risk of exposure to radiological or nuclear accidents around the globe during the forecast period.
The global Anti-Radiation Drugs market is estimated to grow at a CAGR of 8.79% during the forecast period from 2024 to 2030. The demand for anti-radiation drugs is primarily being boosted owing to the increasing number of side effects associated with cancer diagnostic procedures, the surge in the risk of exposure to radiological or nuclear accidents, and the rising inclination of nuclear superpower countries towards radioactive protection among others, thereby contributing to the overall growth of the anti-radiation drugs market during the forecast period from 2024-2030.
Anti-Radiation Drugs Market Dynamics:
According to the FDA, most medical imaging equipment such as Computed Tomography (CT), radiography, and conventional mammography all use ionizing radiation to generate images of the body. These ionizing radiations have enough potential to damage DNA and elevate the risk of developing cancer.
In addition, the National Toxicology Program (NTP) formed from parts of several different US government agencies, including the National Institutes of Health (NIH), the Centers for Disease Control and Prevention (CDC), and the Food and Drug Administration (FDA), has classified x- and gamma radiation as a human carcinogen.
As per the NCI (National Cancer Institute) 2019, patients who have had multiple CT scans before the age of 15 were found to have an increased risk of developing leukemia, and brain tumors. Moreover, sometimes the high levels of radiation exposure can affect tissues and cause hair loss, skin reddening, cataracts, and other problems that might aggravate the need for anti-radiation treatments in the form of drugs.
Therefore, safety concerns due to exposure to high ionizing radiations and their side effects during diagnostic imaging are expected to bolster the demand for anti-radiation pharmaceuticals.
Hence, the interplay of all the above-mentioned factors is anticipated to increase the overall market growth for anti-radiation drugs during the forecast period from 2024 - 2030.
However, the lack of disease-related expertise among healthcare professionals, and ethical and legal complications for finding adequate sample size for clinical trials and research, among others may restrict the growth of the overall market for anti-radiation drugs during the forecast period.
Anti-Radiation Drugs Market Segment Analysis:
Anti-Radiation Drugs Market by Compound (Potassium Iodide, Prussian Blue, Diethylenetriamine Pentaacetic Acid, Colony Stimulating Factors, and others), Indication (Acute Radiation Syndrome, Cancer Treatment, and others), Radiation Type (Ionizing Radiations and Non-Ionizing Radiations), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and others) and Geography (North America, Europe, Asia-Pacific, and Rest of the World).
In the Compound type segment of the anti-radiation drugs market, the Potassium iodide sub-category is expected to amass a significant revenue share in the year 2023. This can be ascribed to the various characteristics and advantages associated with potassium iodide.
One form of radioactive material that can be used to help prevent radioactive iodine (I-131) from being absorbed by the thyroid is potassium iodide (KI), a non-radioactive form of iodine. During a nuclear accident, radioactive iodine may be released into the environment in a plume or cloud and subsequently contaminate soil, surfaces, food, and water.
The best results from KI come from taking it immediately before or right after internal radioactive iodine contamination. The amount of radioactive iodine that enters the body and how quickly it is absorbed by the body both affect how effective KI is.
KI is usually presented in scored tablets, which facilitates fractionation for pediatric dosage. The tablets have also been proven as a protective agent during wars for mass protection.
According to the European Commission (2022) in 2022, during the Ukraine war, the Government of Ukraine ordered KI pills from the European Government as a preventative safety measure to increase the level of protection around the Zaporizhzhia nuclear power plant. The potassium iodide tablets would be used in limited scenarios to avoid that inhaled or swallowed radioactive iodine is absorbed by the thyroid; to which the EU Emergency Response Coordination Centre swiftly mobilized 5.5 million potassium iodide tablets via the EU Civil Protection Mechanism for Ukraine.
Therefore, considering the advantages associated with KI in radioactive protection, it is expected to thereby contribute to the overall market growth for anti-radiation drugs during the forecast period from 2024 to 2030.
North America Is Expected To Dominate The Overall Anti-Radiation Drugs Market:
Among all the regions, North America is estimated to account for the largest share of the Anti-Radiation Drugs market in the year 2023. Owing to the significance of key growth factors such as the presence of a large patient population associated with various diseases including cancers, rising diagnostic procedures, and government protection activities for the masses in North America, the market is expected to witness substantial growth during the forecast period from 2024-2030.
For instance, one of the prominent reasons for the requirement for a high number of anti-radiation drugs is the surge in the prevalence of cancers in the United States. As per the figures mentioned by the American Cancer Society, 2024 data in 2024, it was estimated that approximately 2 million new cancers will be diagnosed in the United States. This ultimately would lead to more demand for anti-radiation drugs resulting from a large number of cancer diagnostic procedures. Moreover, the extensive focus on clinical research and the presence of key players in the region from the pharmaceutical domain further help in the growth of the US anti-radiation drugs treatment market.
Furthermore, in 2022, The US Department of Health and Human Services (HHS) spent USD 290 million on a drug to treat radiation sickness in the event of a nuclear emergency; buying the drug Nplate from Amgen USA Inc. as part of long-standing, ongoing efforts to be better prepared to save lives following radiological and nuclear emergencies.
Therefore, the interplay of all the above-mentioned factors is expected to aid in the growing demand for anti-radiation drugs, thus driving the overall regional market for North America Anti-Radiation Drugs.
Anti-Radiation Drugs Market Key Players:
Some of the key market players operating in the anti-radiation drugs market include Novartis AG, Anbex Inc., Amgen Inc., Myelo Therapeutics, Arco Pharmaceuticals LLC, BTG International Inc., Cellphire Inc., Darnitsa, Enzychem Lifesciences Corporation, Humanetics Corporation, Mission Pharmacal Company, Chrysalis BioTherapeutics Inc., Pluri Inc., Partner Therapeutics, HEYL Chemisch-pharmazeutische Fabrik GmbH & Co. KG., RxBio Inc., Coherus Biosciences, Onconova Therapeutics, Jubilant Life Sciences, Soligenix Inc., and others.
Recent Developmental Activities In The Anti-Radiation Drugs Market:
Key Takeaways From The Anti-Radiation Drugs Market Report Study
Target Audience Who Can Benefit From This Anti-Radiation Drugs Market Report Study
Frequently Asked Questions For The Anti-Radiation Drugs Market:
Anti-radiation drugs are specially formulated medications that could potentially help limit or treat the health effects of certain types of radiation in a radiological or nuclear emergency.
The Anti-Radiation Drugs market is estimated to grow at a CAGR of 8.79% during the forecast period from 2024 to 2030.
The demand for Anti-Radiation Drugs is primarily being boosted owing to the increasing number of side effects associated with cancer diagnostic procedures, the surge in the risk of exposure to radiological or nuclear accidents, and the rising inclination of nuclear superpower countries towards radioactive protection among others, thereby contributing to the overall growth of the anti-radiation drugs market during the forecast period from 2024-2030.
Some of the key market players operating in the Anti-Radiation Drugs market include Novartis AG, Anbex Inc., Amgen Inc., Myelo Therapeutics, Arco Pharmaceuticals LLC, BTG International Inc., Cellphire Inc., Darnitsa, Enzychem Lifesciences Corporation, Humanetics Corporation, Mission Pharmacal Company, Chrysalis BioTherapeutics Inc., Pluri Inc., Partner Therapeutics, HEYL Chemisch-pharmazeutische Fabrik GmbH & Co. KG., RxBio Inc., Coherus Biosciences, Onconova Therapeutics, Jubilant Life Sciences, Soligenix Inc., and others.
North America is expected to dominate the overall Anti-Radiation Drugs market during the forecast period from 2024-2030. Owing to the significance of key growth factors such as the presence of a large patient population associated with various diseases including cancers, diagnostic procedures, and government protection activities for the masses in North America, the market is expected to witness substantial growth during the forecast period from 2024-2030.